Epic Sciences

Epic Sciences? revolutionary circulating tumor cell (CTC) detection platform begins with a single, non-invasive blood draw. From this sample, we conduct multiparametric, single cell analysis of protein expression, cell morphology and single cell genomics to see the widest biological range of cells with unmatched sensitivity. We develop new, highly sensitive diagnostic tests that identify and molecularly characterize circulating tumor cells (CTCs) in the blood to provide a better way to detect cancer and personalize and monitor treatments. The AR-V7 test is the first and only Medicare reimbursed, clinically-validated, predictive circulating tumor cell (CTC) liquid biopsy test for metastatic castration-resistant prostate cancer (mCRPC). Requiring only a simple, non-invasive blood draw, this groundbreaking test empowers patients, with their doctors, the confidence to choose the most effective precision therapies. For pharmaceutical and clinical investigation partners, our Decision Point program delivers a bias-free approach for cancer research, to develop clinical solutions that accelerate drug development and provide valuable insights into the dynamics of cancer growth, evolution and heterogeneity. Mission: Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic?s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient?s journey. Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point.